Esketamine NS induces higher remission and response rates in treatmentresistant depression patients: The ESCAPE-TRD trial

Personal recovery - achieving a true recovery from schizophrenia

Depression, inflammation, and glucocorticoid resistance: A possible causal triangle

6-month paliperidone palmitate is effective and well-tolerated in patients with schizophrenia

Promoting paradigm shift in mental disorder treatment: The empirical schizophrenia staging system

Unraveling the interplay between stress, immune responses, and metabolic indicators in major depression